Medicine and Dentistry
Genotype
100%
Prognosis
100%
Hepatocellular Carcinoma
100%
Sorafenib
100%
Patient
75%
Overall Survival
37%
Combination Therapy
25%
Regression Analysis
25%
Hepatitis B Antigen
25%
Proportional Hazards Model
25%
Cells
12%
Analysis
12%
Assay
12%
Inpatient
12%
Promoter Region
12%
Tyrosine-Kinase Inhibitor
12%
Hepatoma Cell
12%
Targeted Therapy
12%
Hepatitis B
12%
Hepatitis C Virus
12%
Hepatitis B Virus X Protein
12%
Virus Antibody
12%
Gastrointestinal Cancer
12%
Nursing and Health Professions
Prognosis
100%
Liver Cell Carcinoma
100%
Sorafenib
100%
Lenvatinib
62%
Overall Survival
37%
Regression Analysis
25%
Treatment Outcome
25%
Proportional Hazards Model
25%
Hepatitis B Surface Antigen
25%
Vascular Guide Wire
25%
Combination Therapy
12%
Assay
12%
Analysis
12%
Hepatitis B
12%
Protein Tyrosine Kinase Inhibitor
12%
Hepatitis C
12%
Virus Antibody
12%
Treatment Response Time
12%
Hepatitis B Virus X Protein
12%
Digestive System Cancer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Prognosis
100%
Sorafenib
100%
Lenvatinib
62%
Overall Survival
37%
Hepatitis B Surface Antigen
25%
Protein Tyrosine Kinase Inhibitor
12%
Hepatitis B
12%
Hepatitis C Virus
12%
Hepatitis B Virus X Protein
12%
Virus Antibody
12%
Digestive System Cancer
12%